Associate Director, Commercial Business Solutions

Stemline Therapeutics; United States; On-site; USD 90,000 - 150,000; Full time

Job summary

Join a forward-thinking biopharmaceutical company as an Associate Director, Commercial Business Solutions. This pivotal role involves driving analytics and reporting solutions for commercial teams, ensuring effective field operations and collaboration across departments. You will leverage your expertise in advanced analytics and sales operations to enhance the performance of a dedicated field team. This is an exciting opportunity to contribute to innovative oncology solutions and help shape the future of patient care. If you are a strategic thinker with a passion for analytics and collaboration, we invite you to be part of this dynamic organization.

Qualifications

• 7+ years in pharma/biotech with management experience preferred.
• Expertise in sales operations and analytics for field teams.

Responsibilities

• Manage field reporting, CRM, and third-party tools for the commercial team.
• Collaborate with BI for field performance reporting and insights.

Skills

Advanced Analytics

Sales Operations

Veeva CRM

Data Manipulation

Collaboration

Project Management

Education

Bachelor's Degree in Business

Advanced Degree in Related Field

Tools

SAS

Alteryx

R

Python

SQL

Tableau

Qliksense

Job description

Overview

Associate Director, Commercial Business Solutions

Reports to AVP Commercial Excellence Lead

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialise Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global licence agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

Menarini’s commitment to oncology is also reflected in the investments made in the liquid biopsy diagnostic field through its affiliate Menarini Silicon Biosystems (MSB), a pioneer in rare cell analysis and non-invasive, advanced diagnostic solutions. MSB’s CELLSEARCH Circulating Tumour Cell (CTC) Test is the first and only clinically validated blood test cleared by the U.S. Food & Drug Administration (FDA) for detecting and counting CTCs in metastatic breast, prostate, and colorectal cancer when used in conjunction with other clinical monitoring methods.

Since 2021, MSB has offered in the US a menu of non-invasive Laboratory Developed Tests (LDTs) provided through its CLIA/CAP accredited US-based Lab. The services include CMC enumeration, CTC enumeration and PDL-1/HER2 biomarker and offer a minimally invasive approach to follow cancer patient’s therapeutic journey.

In 2022, the company launched the CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) Enumeration LDT, the first-of-its-kind, which directly measures levels of plasma cells in the blood of patients. This test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, it can be performed serially to assess plasma cell burden without requiring repeated bone marrow biopsies.

Menarini's vision and uniqueness in oncology is to bring together innovative therapeutic solutions and advanced liquid biopsy-based diagnostics for faster, more effective and precise patient management.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.

Responsibilities

Opportunity

Associate Director, Commercial Business Solutions is responsible for providing expertise around the implementation and maintenance of field tools for Commercial Organization in the US, for Orserdu, Elzonris and any future indications/drugs. This role will report to AVP, Commercial Excellence

Responsibilities

• Business owner of field reporting, CRM, field alignments/targeting and any other third party tools implemented for field teams, including but not limited to HCP appointment portal, rewards portal, vehicle reimbursement portal. Also the point person for the questions from the field and addressing them working closely with other commercial leads and cross-functional partners (as needed)
• Field Reporting: Be responsible for automation, visualization, enhancement and maintenance of field reporting solution, including reporting on sales, activities, performance, etc., for field teams from commercial and market access (including but not limited to sales, marketing, Field reimbursement, Key Account Directors, Payer team). Collaborate closely with partners such as BI team for development of the field performance reporting strategy and implement a robust and flexible reporting system to ensure timely and accurate insights that drive business decisions.
• Veeva CRM and Vault: Ensure the continued improvement, enhancement and maintenance of Veeva solutions, from commercial team’s perspective. This includes automation of field feedback on call plan and Incentive Compensation Address Management as well as any improvements in Veeva Vault. Provide troubleshooting support to field reporting and Veeva platform, in collaboration with business intelligence. Work closely with Marketing to roll out new documents, messaging and intelligent alerts/Veeva suggestions.
• Alignment and Targeting: Be responsible for creation, update and maintenance of alignment and targeting across various field teams and use the appropriate tools and process for time, cost and quality improvements.
• Vehicle reimbursement tool: Be responsible for implementing the rules, reimbursement limits by territory, any compliance requirements, training, monthly approvals (working with cross functional partners)
• Bravissimo Rewards Portal: Be responsible for upgrades, rollouts, maintenance, training and approvals of the rewards portal.
• Field Roster Management: Automate, optimize and maintain field roster, ensuring timely onboarding and offboarding of field colleagues across various field business solutions.
• Training on field tools: Be responsible for documentation and training on field business solution, including but not limited to, field reporting, Veeva CRM, HCP appointment portal, bravissimo rewards portal, Vehicle reimbursement portal, etc.
• Business Question Central (BQC): Be responsible for addressing all questions from field teams and triage them to appropriate team, as needed. Example: Triage IC questions to Director, Field Operations while work with vehicle reimbursement partner and HR to address any questions around vehicle use reimbursement.
• Work closely with the AVP, Commercial Excellence and other team members to support Veeva system and related reporting for various field teams from Commercial, Medical Affairs, etc.

Qualifications

Skills/Knowledge

Minimum of a Bachelor's degree in Business, Analytics, Finance, or related field; equivalent experience may be accepted. Related advanced degree preferred.

• 7+ years of relevant experience in pharma/biotech space in advanced analytics; 4+ years of management experience preferred
• Previous experience working in the pharmaceutical/biotechnology industry required

• Previous Hem/Onc and/or Solid tumor analytics, business solutions or field operations experience required
• Expertise in sales operations processes a must, including but not limited to call plan, alignment, Veeva CRM, Reporting solutions, supporting a 50+ field team
• Must be a strong collaborator working closely with IT, Compliance, HR, Finance, Medical Affairs and Commercial (sales, marketing, market access) partners
• High degree of creativity and innovation in developing new approaches, processes and methodologies.
• Experience working with large complex data and corresponding query/ programming languages such as SAS, Alteryx, R, Python, or SQL plus experience with other big data technology such as Hadoop and front-end tools such as Tableau, Qliksense, Veeva
• Experience with field force analytics, including customer segmentation, targeting, promotional response measurements and omni-channel marketing.
• Proficiency in manipulating and extracting insights from large longitudinal data sources, such as Claims, EMR and other patient level data sets.
• Strong interpersonal skills and a consultative mindset, with the ability to develop strong partnerships and influence without authority.
• Excellent oral and written communication skills; including describing complex data topics in simple terms.
• Strong organizational skills and time management; ability to manage diverse range of simultaneous projects.

Please note--this position is classified as a corporate office position. In accordance with the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.

Menarini Stemline is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.